Compare Amgen, Inc. (AMGN) vs Gap Inc (GAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Gap Inc — how do they compare? Amgen, Inc. trades at $413.6 (market cap $225.71B), while Gap Inc trades at $21 (market cap $7.74B). The key difference: Amgen, Inc. is far larger — about 29.2× Gap Inc's market cap, and Gap Inc pays the higher dividend (3.25%). Which is the better fit depends on your goals.
| AMGN | GAP | |
|---|---|---|
Market Cap | $225.71B | $7.74B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $29.13 |
52-Week Low | $271.18 | $18.35 |
Enterprise Value | $269.02B | $10.82B |
Dividend Yield | 2.42% | 3.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
Gap trades at $20.47, down 0.24% on the day, with a bullish technical signal supported by strong momentum indicators. The stock shows attractive valuation metrics, including a P/E of 8.12 and P/S of 0.51, while recent earnings have generally beaten expectations. Operating cash flow remains robust at $1.49 billion for 2025, and the company continues its digital transformation with AI initiatives.
The outlook is positive with a consensus price target of $26.64, implying 30% upside. Risks include competitive pressures and ongoing investigations by Pomerantz Law Firm. Analyst sentiment is mixed but leans bullish, with 39.58% recommending buy. The stock presents a value opportunity if turnaround efforts sustain momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
